Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases

Active

Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health is forecasting a contract for the development of medical countermeasures aimed at biodefense and emerging infectious diseases. This initiative falls under NAICS code 541714, focusing on research and experimental development in the field of biotechnology. The project is managed by the National Institutes of Health, with Paul Eder serving as the Program Point of Contact and Alexandra Buck acting as the Contracting Officer. Further details regarding this opportunity can be accessed through the HHS Office of Small and Disadvantaged Business Utilization portal.

General Info

NIH seeks biotechnology research for medical countermeasures against biodefense and emerging infectious diseases.

Agency

National Institutes of Health → National Institutes Of Health

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

USA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyNational Institutes of Health → National Institutes Of Health

Contacts2 people available

OfficeN/A

Organization / AgencyNational Institutes of Health → National Institutes Of Health

Office AddressN/A

Contacts

Paul Eder

contact@example.gov

Alexandra BuckContracting Officer

contact@example.gov

Full Description

Show more

Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases

Similar Contracts

Same NAICS industry code

Immunohistochemical (IHC) Analysis SupportThe Immunohistochemical (IHC) Analysis Support subcontract, issued by the NASA Shared Services Center, involves providing specialized staining and chemical analysis of sectioned tissue for prime contractors on NASA Space Biosciences projects. The scope of work requires the application of antibodies and reagents to cryo-sectioned slides and the use of fluorescence microscopes and IHC staining stations to evaluate neuronal morphology. Due to the technical nature of the work, specialized training in neuro-histology is required to deliver the final analyzed slides and digital imaging reports. This opportunity is categorized under NAICS code 541714 and is associated with a performance location in zip code 94035. The solicitation was posted on November 4, 2026, with a response deadline of November 9, 2026.

NASA Shared Services Center

POSTED

about 17 hours ago

DEADLINE

Service request for specimen embedding and sectioning.

Solicitation # 80NSSC27948767Q

The NASA Shared Services Center is seeking custom histology research services to support a Space Biosciences Project evaluating neuronal morphology in mouse brains exposed to radiation, isolation, and simulated microgravity. The scope of work involves planning, preliminary testing, embedding, and cryo-sectioning of specific brain regions, including the substantia nigra, hippocampus, and prefrontal cortex. The contractor must provide slides with sections 15 microns thick, which are to be delivered to Principal Investigator Dr. Joshua Alwood within 90 days after receipt of order. Performance will be located at the NASA Ames Research Center. This procurement is being conducted under FAR Part 12 for commercial items and services, with the government intending to issue a sole source contract to ZYAGEN, identified as the sole provider of the required services. While the agency is currently requesting capability statements from interested organizations by November 9, 2026, to determine if a competitive procurement is feasible, it explicitly states that quotes will not be reviewed or accepted at this stage. Primary coordination for this effort is managed by Cara Craft and Will Garrett.

NASA Shared Services Center

POSTED

about 17 hours ago

DEADLINE

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-014

The National Institutes of Health (NIH) issued solicitation RFA-AI-28-014 to establish centers focused on the systems-level understanding of the links between infectious pathogens, inflammatory pathways, and chronic diseases. The program supports two types of centers: Chronic and Infectious Diseases Systems Biology Centers (CIDSB), which examine the bidirectional link between chronic and infectious diseases, and Systems Biology Inflammation Centers (SBI), which focus on the role of inflammation in chronic diseases to identify precision medicine targets. The primary goals are to develop predictive computational models for disease progression, discover novel drug targets and biomarkers, and create harmonized, FAIR-compliant cross-disease datasets. The total program funding is 26 million dollars, with an expected 10 awards and an individual award ceiling of 2.5 million dollars. Applications must be submitted electronically via Grants.gov by February 18, 2027. The proposal structure is multi-component, requiring an overall section, an administrative core, a data and modeling core, and a biospecimen collection and processing core, with additional requirements for research projects and optional cores depending on the center type. Evaluation is based on an overall impact score focusing on significance and the qualifications of the investigators. Awardees must comply with strict cybersecurity incident reporting requirements, notifying the HHS awarding agency within 48 hours of discovery, and must adhere to rigorous biosafety and human subjects protection standards. Applicants must maintain active SAM registration and UEI identifiers to be eligible for funding.

National Institutes Of Health

POSTED

about 24 hours ago

DEADLINE

In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.

National Institutes Of Health

POSTED

DEADLINE

in over 2 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

Solicitation PAR-28-042, issued by the National Institutes of Health under the Department of Health and Human Services, is a funding opportunity designed to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer. The program focuses on tools for cancer detection, diagnosis, prognosis, monitoring, and the prediction of treatment response or toxicity. Funding is available through either a phased UH2/UH3 mechanism or a standalone UH3 mechanism to facilitate laboratory optimization and clinical validation using human samples. Key deliverables include the demonstration of assay results associated with clinical endpoints, the establishment of statistical cut-off values, and the definition of sensitivity and specificity. All clinical laboratories must adhere to CLIA, GLP, or ISO 17025 standards. Awards are determined via a peer review system based on an overall impact score, evaluating the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Specific evaluation criteria include the clarity of milestones for transitioning from UH2 to UH3 phases and the adequacy of commercialization plans. Eligible applicants include small businesses, for-profit organizations, higher education institutions, and 501(c)(3) nonprofits. Applicants must maintain active registrations in SAM.gov, eRA Commons, and Grants.gov. Additionally, recipients must comply with strict cybersecurity incident reporting requirements, notifying the agency within 48 hours of discovery, and ensure all human subject protocols are reviewed by an Institutional Review Board or Independent Ethics Committee.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Specialized Bioscience Research & AnalysisThe Specialized Bioscience Research and Analysis subcontract, issued by the Biotechnology and Biological Sciences Research Council under UK Research and Innovation, focuses on advancing the understanding of living systems through curiosity-driven research. The selected provider will support prime contractors on bioscience discovery projects by performing advanced biological research, laboratory analysis, and experimental validation. Key technical requirements include the use of high-throughput sequencing and advanced microscopy, with a final delivery expectation of comprehensive experimental data and peer-reviewed publications. To qualify for this engagement, providers must possess PhD or Post-doc credentials and maintain valid institutional biosafety certifications. The project emphasizes team science methodologies to achieve its research goals. Interested parties must submit their responses by February 9, 2027, in accordance with the solicitation posted on November 3, 2026.

Biotechnology and Biological Sciences Research Council (BBSRC)

POSTED

DEADLINE

2026 to 2027 strategic Longer and Larger (sLoLa): full stage

Solicitation # 189488

The Biotechnology and Biological Sciences Research Council (BBSRC), under UK Research and Innovation (UKRI), is soliciting proposals for the 2026 to 2027 Strategic Longer and Larger (sLoLa) program. This initiative funds large-scale, team-based, curiosity-driven bioscience discovery research projects aimed at achieving major breakthroughs in the fundamental understanding of living systems. Eligible projects must utilize a fully integrated team science approach, demonstrate a need for extended and large-scale funding, and enhance the overall capability and capacity of UK biosciences. Projects can last up to five years, and the full economic cost must exceed 2 million pounds, with BBSRC providing 80 percent of that cost. The selection process is conducted in two stages. The outline stage opened on April 16, 2026, and closed on June 25, 2026, with evaluations based on vision, approach, and team capability. Successful outline applicants are invited to the full stage, which opened on November 5, 2026, and closed on February 9, 2027. Full proposals are evaluated via external peer review and a multidisciplinary panel, focusing on management strategy and strategic case. Final funding recommendations are made by the Strategic LoLa Committee following an interview process with the highest-rated teams. All applications are managed through the UKRI Funding Service.

Biotechnology and Biological Sciences Research Council (BBSRC)

POSTED

DEADLINE

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Solicitation # PAR-28-042

The National Cancer Institute, under the National Institutes of Health, has issued solicitation PAR-28-042 to provide funding for the analytical and clinical validation of biomarkers and assays related to cancer. This initiative focuses on molecular, cellular, and imaging markers used for detection, diagnosis, prognosis, treatment response, prevention, and toxicity monitoring. The goal is to support laboratory optimization and validation for assays using human samples that address specific clinical needs and intended uses. Eligible projects may utilize either a standalone UH3 mechanism or a phased UH2/UH3 approach, though clinical trials are explicitly not allowed. The solicitation was posted on November 3, 2026, with a response deadline set for November 17, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institute of Neurological Disorders and Stroke, under the National Institutes of Health, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias. This initiative covers a broad range of conditions, including Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program is designed to advance the translational pipeline from initial therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Eligible activities include the optimization of delivery systems and editing constructs, the assessment of bioactivity and pharmacokinetics, and the demonstration of in vivo efficacy. Additionally, the funding supports safety pharmacology, toxicology studies, and the creation of scalable manufacturing processes and quality attributes that meet regulatory standards. This solicitation was posted on November 3, 2026, with a response deadline of October 11, 2028.

National Institute Of Neurological Disorders And Stroke

POSTED

DEADLINE

in almost 2 years

More opportunities from National Institutes of Health → National Institutes Of Health

Same awarding agency

Draft Policy Update to the NIH Policy for Data and Safety Monitoring

Solicitation # NOT-OD-27-006

The National Institutes of Health is proposing to update its 1998 Policy for Data and Safety Monitoring to expand its scope from clinical trials to all NIH-supported clinical research. This update introduces a risk-based approach to data and safety monitoring, requiring a monitoring plan tailored to the specific risks of each study to ensure participant safety and data integrity while reducing administrative burdens for lower-risk research. Key changes include removing the mandatory requirement for Data and Safety Monitoring Boards for all phase 3 or multi-site clinical trials, instead allowing for flexible, proportionate oversight approved by NIH Institutes, Centers, and Offices. Under the proposed policy, recipients and investigators must conduct risk assessments and implement approved monitoring plans prior to starting human subject activities. The policy defines roles for investigators, sponsors, and independent monitors, and establishes compliance mechanisms that may include funding termination for non-compliance. NIH is currently seeking public feedback on the draft policy and potential supplemental resources, such as templates and guidance tools, with comments accepted until January 6, 2027.

Other Management Consulting Services

POSTED

DEADLINE

USG Policy for the use of Super Intelligence

Solicitation # NOT-OD-27-011

The National Institutes of Health is implementing a policy transition mandated by Executive Order 14434, which requires the federal government to replace the terms Artificial Intelligence and AI with Super Intelligence and SI in all official documents, reports, websites, and public communications. This directive ensures standardized terminology across federal agencies to describe advanced machine-based systems. Under this policy, Super Intelligence is defined as a system capable of making predictions, recommendations, or decisions to influence real or virtual environments based on human-defined objectives. These systems are characterized by their ability to perceive environments, automate the creation of models through analysis, and use model inference to determine specific options for information or action.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

NIH Operates Under a Continuing Resolution

Solicitation # NOT-OD-26-131

The National Institutes of Health is operating under the Continuing Appropriations and Extensions Act, 2027, which extends government operations through December 11, 2026, at the Fiscal Year 2026 enacted level. Under this resolution, the NIH is prohibited from implementing revisions to the Uniform Administrative Requirements for Federal Awards until the expiration date. Additionally, NIH Institutes and Centers maintain the discretion to issue non-competing research grant awards at levels lower than those listed on the most recent Notice of Award, with potential upward adjustments considered only after FY 2027 appropriations are enacted. All legislative mandates and fiscal policies from FY 2026 remain in effect, including the salary limitation set at Executive Level II of the Federal Pay Scale. The Ruth L. Kirschstein National Research Service Award stipend levels and tuition fees also remain consistent with previous notices. Institutions are expected to monitor their expenditures closely during this period to ensure financial stability until new appropriations are finalized.

Administration of Public Health Programs

POSTED

about 1 month ago

DEADLINE

Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)

Solicitation # RFA-OD-27-009

The National Institutes of Health is forecasting a limited competition to establish five new Research Evaluation and Commercialization Hubs (REACH). This program is designed to transition biomedical discoveries from academic settings into commercial products that enhance public health and patient care. Eligible colleges, universities, and nonprofit organizations will compete to create hubs that provide researchers with early-stage funding, technical resources, and mentorship in product development, regulatory navigation, and business management. These hubs will operate as a technology development consortium focused on high-priority technologies and the creation of prototypes and proof-of-concept studies. The program emphasizes public-private partnerships and non-federal matching funds to support federal priorities, including workforce development and the delivery of healthcare solutions to rural and underserved areas. While applications are not yet being solicited, this forecast allows potential applicants to establish the necessary collaborations for the upcoming peer-review process.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

IT Governance & Enterprise ArchitectureThe contract supports the National Institutes of Health in governing its IT systems, aligning strategic planning with federal mandates, and ensuring enterprise architecture integrity across its operations. It focuses on providing expert guidance to harmonize NIH’s technology initiatives with broader government standards, enhancing efficiency, compliance, and interoperability within the Department of Health and Human Services. The work will be performed primarily in Bethesda, Maryland, with the NAICS code 541611 indicating it is a professional, scientific, and technical services subcontract related to management consulting services. As a subcontract, this effort is embedded within a larger procurement structure and does not carry an advertised set-aside designation, meaning it is open to any qualified business entity capable of delivering the required capabilities. The opportunity was posted in June 2026 and is accessible through the SAM.gov portal for potential bidder consideration.

Administrative Management and General Management Consulting Services

POSTED

DEADLINE

Tier 2 Help Desk & End-User SupportThe contract is for Tier 2 Help Desk and End-User Support services to be provided to staff of the National Institutes of Health under the Department of Health and Human Services. It requires comprehensive technical assistance covering hardware, software, and network issues, with responsibilities including ticket intake, prioritization, escalation, and final resolution. Services will be performed primarily at the Bethesda location with a ZIP code of 20892, ensuring on-site or closely coordinated support for NIH employees. This is a subcontract under NAICS code 541519, indicating it falls under other computer-related services, and was posted for opportunity on June 25, 2026. The contract does not specify a set-aside type or detailed point of contact, and all work must align with NIH’s internal support standards and escalation procedures.

Other Computer Related Services

POSTED

DEADLINE

Network Operations & SupportThe contract titled Network Operations & Support is a subcontract awarded by the National Institutes of Health under the U.S. Department of Health and Human Services to manage and sustain the NIH enterprise network infrastructure. The work encompasses continuous monitoring, troubleshooting, and performance optimization of critical network systems to ensure operational reliability and efficiency. The primary place of performance is in Bethesda, Maryland, with a zip code of 20892, indicating the physical location where services will be delivered. The contract falls under NAICS code 541513, which classifies it as Computer Systems Design and Related Services, emphasizing its technical and IT infrastructure focus. Although the solicitation number and point of contact are not provided, the posting date of June 25, 2026, suggests this is a future opportunity, and the contract is structured as a subcontract, meaning it is part of a larger prime contract arrangement. There is no set-aside designation specified, indicating it is open to all eligible contractors without preferential treatment based on business size or category.

Computer Facilities Management Services

POSTED

DEADLINE

Cybersecurity Operations & ComplianceThe contract titled Cybersecurity Operations & Compliance is a subcontract under the National Institutes of Health, part of the Department of Health and Human Services, aimed at delivering continuous cybersecurity monitoring, real-time threat detection, rapid incident response, and policy compliance services for NIH IT systems. The work is performance-based and requires the contractor to maintain robust, 24/7 operational capabilities to identify, analyze, and mitigate cyber threats across NIH infrastructure, ensuring alignment with federal security standards and regulatory requirements. The place of performance is designated as Bethesda, Maryland, with a zip code of 20892, indicating the primary location for service delivery, even though no specific office address or point of contact is provided. The contract is classified under NAICS code 541612, which corresponds to Computer Facilities Management Services, signaling that the focus is on managed cybersecurity operations rather than hardware or software procurement. It was posted on June 25, 2026, suggesting this is a future opportunity under solicitation, though no solicitation number is listed. As a subcontract, this effort supports a prime contractor or larger program, meaning the successful bidder will integrate their services into an existing cybersecurity framework. The absence of set-aside information implies the opportunity may be open to all eligible small or large businesses without specific socioeconomic preferences. The contractor must be prepared to operate at a high tempo, maintain strict compliance, and respond effectively to evolving cyber threats impacting critical health research systems.

Human Resources Consulting Services

POSTED

DEADLINE

Application Modernization & Software DevelopmentThe contract seeks to modernize legacy applications used by the National Institutes of Health through refactor, re-platform, or full rebuild efforts aligned with contemporary software development practices. The work will emphasize the integration of artificial intelligence and automation technologies to improve efficiency, scalability, and maintainability of critical health research systems. Performance is specifically required to occur in Bethesda, Maryland, with the North American Industry Classification System code 541511 indicating the focus on custom computer programming services. This subcontract opportunity is positioned under the Department of Health and Human Services and is intended to support NIH’s broader digital transformation goals by transitioning outdated systems to robust, future-ready platforms capable of handling evolving research and data needs.

Custom Computer Programming Services

POSTED

DEADLINE

Cloud Infrastructure Migration & ModernizationThe contract involves the migration and modernization of enterprise applications and data systems for the National Institutes of Health into secure cloud environments, requiring comprehensive architecture design, deployment, and seamless integration with existing infrastructure. The work focuses on enhancing security, scalability, and operational efficiency by transitioning legacy systems to modern cloud-based platforms, ensuring continuity and compliance with federal standards. The contract is classified as a subcontract under NAICS code 541512 for other computer related services, with performance located in Bethesda, Maryland, 20892. It was posted on June 25, 2026, and is part of the Department of Health and Human Services initiative to advance NIH's digital capabilities. There is no specified set-aside type, and the point of contact information is not provided, though the work is central to modernizing critical health research systems within a highly regulated environment.

Computer Systems Design Services

POSTED

DEADLINE

NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)

Solicitation # PA-27-101

The NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award, solicitation PA-27-101, is designed to bridge the funding gap between the completion of an SBIR or Small Business Technology Transfer (STTR) Phase II award and full commercialization. This program provides previously funded NIH projects with additional support for later-stage research and development. Applications are evaluated through the NIH peer review system based on scientific and technical merit, specifically focusing on significance, the qualifications of the investigators, and the suitability of the scientific and business environment. While clinical trials are optional, projects involving human subjects must adhere to strict safety monitoring and registration requirements via ClinicalTrials.gov. Financial support varies by participating institute, with budget limits ranging from 3 million dollars to 15 million dollars, though total funding support may not exceed 30 million dollars. A critical requirement for this award is a 100 percent cost match sourced from new private capital or non-SBIR/STTR government funding. Applicants must maintain active registrations in the System for Award Management (SAM), possess a Unique Entity Identifier (UEI), and be registered in the SBA Company Registry. Required submission materials include a detailed commercialization plan, a finance plan, and a regulatory plan limited to two pages. Additionally, recipients must implement a cybersecurity incident response plan and notify the HHS of any breaches within 48 hours of discovery.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria – A Model for Mosquito-Borne Diseases

Solicitation # RFA-AI-28-024

The National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, is forecasting an opportunity to fund basic research, discovery, and preclinical development of highly effective vaccines for malaria and other mosquito-borne illnesses. The program emphasizes the use of novel vaccine design strategies, specifically focusing on structure-based immunogen design and combination vaccines intended to lower parasite infection rates and reduce the overall disease burden. This initiative is categorized under NAICS code 541715 and is managed by the Department of Health and Human Services. Interested parties can contact the Malaria and Other Mosquito Borne Diseases office for further information regarding this forecast, which aims to leverage recent technological innovations to advance next-generation vaccine development.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS